E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.
Michael Andreeff,Gautam Borthakur,Zhihong Zeng,Mary A. Kelly,Rui-Yu Wang,Teresa McQueen,Yihua Qiu,Duncan Mak,Jan A. Burger,Naval Daver,Naveen Pemmaraju,Tapan M. Kadia,Elias Jabbour,Sherry Pierce,Farhad Ravandi,Guillermo Garcia-Manero,Susan O'Brien,Jorge E. Cortes,Hagop M. Kantarjian,Marina Konopleva +19 more
TL;DR: The group identified sorafenib (S) as potent inhibitor of FLT3-ITD mutant AML and demonstrated increased preclinical activity of S, which is associated with poor prognosis.
Journal ArticleDOI
Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy
Alfonso Quintás-Cardama,Sangbum Choi,Hagop M. Kantarjian,Elias Jabbour,Xuelin Huang,Jorge E. Cortes +5 more
TL;DR: A calculator to predict future outcomes of patients with CML at any time point during the course of therapy is designed and no differences were observed regarding future outcomes between patients treated with imatinib or dasatinib in the frontline setting.
Journal ArticleDOI
Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience
Prajwal Boddu,Guillermo Garcia-Manero,Farhad Ravandi,Gautam Borthakur,Elias Jabbour,Courtney D. DiNardo,Nitin Jain,Naval Daver,Naveen Pemmaraju,Paolo Anderlini,Simrit Parmar,Devendra Kc,Mary Akosile,Sherry Pierce,Richard E. Champlin,Jorge E. Cortes,Hagop M. Kantarjian,Tapan M. Kadia +17 more
TL;DR: There was no survival difference between IST and allogeneic stem cell transplant groups, with a trend toward superior OS in the former, and Transplant benefits in the R/R setting may be underrealized due to transplant‐related mortality.
Journal ArticleDOI
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias
TL;DR: Nilotinib (Tasigna®) is a novel potent selective oral kinase inhibitor that effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML postImatinib failure.
Journal ArticleDOI
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
Nicholas J. Short,Elias Jabbour,Farhad Ravandi,Xuelin Huang,Nitin Jain,Koji Sasaki,Naveen Pemmaraju,Naval Daver,Joseph D. Khoury,Jeffrey L. Jorgensen,Yesid Alvarado,Marina Konopleva,Guillermo Garcia-Manero,Tapan M. Kadia,Musa Yilmaz,Gautam Borthakur,Jan A. Burger,Steven M. Kornblau,William G. Wierda,Courtney D. DiNardo,Alessandra Ferrajoli,Patrice Nasnas,Jovitta Jacob,Rebecca E. Garris,Susan O'Brien,Hagop M. Kantarjian +25 more
TL;DR: The promising efficacy and survival of INO in combination with low-intensity mini-hyper-CVD chemotherapy in older adults with newly diagnosed ALL was reported and the 30-day and 60-day mortality rates were 0% and 3%, respectively.